News
-
-
-
PRESS RELEASE
Applied DNA Positions TR8 PGx Testing Service as Pre-Emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
Applied DNA Sciences announces repositioning of TR8™ PGx testing service to offer tailored subpanels targeting genetic variants correlated with DPD enzyme deficiencies in cancer patients, following recent FDA safety announcement -
PRESS RELEASE
Original-Research: Lisata Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates Lisata Therapeutics Inc (ISIN: US1280583022) research with a Buy recommendation and USD 15.00 target price. Lisata's FY/24 results exceeded expectations, with promising developments in certepetide trials and AI collaboration -
-
-
-
PRESS RELEASE
SYNBIOTIC presents medical cannabis as a pastille for the German market for the first time
SYNBIOTIC SE presents medical cannabis pastilles on the German market for the first time, offering a new, personalized, and effective dosage form. Partnering with BOLDER Arzneimittel, this innovation sets new standards for cannabis therapy -
-